A New Supporter
Stephanie Sutton |
Initially, The American College of Rheumatology urged caution around the use of biosimilars. Information about the manufacturing process for a branded biologic is proprietary; a biosimilar manufacturer will not have access to the details of the process so how could they guarantee their product would be the same? It is now well accepted by the scientific community that biosimilars are safe, and in February 2018 ACR published a white paper, The Science Behind Biosimilars – Entering a New Era of Biologic Therapy (1), which aims to educate ACR members about and support the use of biosimilars.
“Increased real-world experience with biosimilars in Europe, new data including a prospective switching study (NOR-SWITCH), and increasing clarity around FDA policies (naming, switching) have all served to increase confidence in biosimilars,” explains Doug White, one of the authors of the paper and ACR Board of Directors member at large.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.